You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國產疫苗股走強 全國累計接種新冠疫苗超2億劑次
格隆匯 04-22 10:57
格隆匯4月22日丨國產疫苗股走強,康希諾生物-B(06185.HK)漲近6%,康希諾(688185.SH)漲7.4%,國藥控股亦漲近3%。據國家衞健委,目前,全國累計報吿接種新冠疫苗超過2億劑次。目前還沒有觀察到接種國產康希諾腺病毒載體新冠疫苗導致血栓的報吿,藥監部門將會持續監控。此外,中國核心學術期刊《中華流行病學雜誌》刊登了題為“新型冠狀病毒滅活疫苗(Vero細胞)大規模緊急使用安全性評價”的論文,發佈基於國藥集團中國生物北京製品研究所、武漢生物製品研究所新型冠狀病毒滅活疫苗大規模緊急使用安全性評價。研究表明,大規模新型冠病毒滅活疫苗(Vero細胞)進行緊急使用後,一般反應的發生率較低,未見嚴重不良反應,疫苗具有良好的安全性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account